Efficacy and Safety of Higher Doses of Levofloxacin For Multidrug-resistant Tuberculosis: a Randomized, Placebo-controlled Phase ii Clinical Trial.

Details

• Alternative Title:
  American Journal of Respiratory and Critical Care Medicine, 2025, v. 211, no. 7: Efficacy and Safety of Higher Doses of Levofloxacin For Multidrug-resistant Tuberculosis: a Randomized, Placebo-controlled Phase ii Clinical Trial.
• Journal Article:
  American Journal of Respiratory and Critical Care Medicine
• Personal Author:
  Phillips, PPJ ; Peloquin, C.A. ; Sterling, Timothy R. ; Kaur, P. ; Diacon, A.H. ; Gotuzzo, Eduardo ; Benator, D. ; Warren, R.M. ; Sikes, D. ; Lecca, L. ; Gandhi, N.R. ; Streicher, E.M. ; Dianis, N. ; Eisenach, K. ; Mitnick, C.D. ; Horsburgh, C.R.
• Corporate Authors:
  the OptiQ study team
• Description:
  Evaluation of optimal dosing has generally been inadequate during tuberculosis (TB) drug development. Fluoroquinolones are central to TB treatment.
  
  To determine the dose of levofloxacin needed to achieve maximal efficacy and acceptable safety and tolerability as part of a multidrug TB regimen.
  
  Opti-Q was an international, multicenter, randomized, placebo-controlled phase II trial. Eligible participants with TB resistant to isoniazid and rifampicin but susceptible to fluoroquinolones were randomized to receive one of four weight-adjusted once-daily doses of levofloxacin for 24 weeks (168 doses) alongside a multidrug regimen: 11 mg/kg (750 mg), 14 mg/kg (750 mg/1,000 mg), 17 mg/kg (1,000 mg/1,250 mg) or 20 mg/kg (1,250 mg/1,500 mg). The primary efficacy outcome was time to sputum culture conversion, and the primary safety outcome was grade ≥3 adverse events (AEs).
  
  A total of 111 participants were randomized from three sites in South Africa and Peru. Eighty-three (75%) had cavities on chest X-ray, 55 (50%) had a smear grading of 3+, and the median body mass index was 20.4 kg/m
  
  . Median levofloxacin areas under the curve (AUCs)/minimum inhibitory concentrations were 573, 633, 918, and 1,343 across the four treatment arms. There was no difference in time to culture conversion on solid or liquid media by treatment arm (stratified log-rank
  
   = 0.282), by tertile of AUC/minimum inhibitory concentration (
  
   = 0.350), or by dose received (
  
   = 0.723); 69.3%, 74.8%, 70.6%, and 78.3% exhibited culture conversion after 8 weeks on solid media, respectively, across the treatment arms; along with 64.6%, 69.5%, 52.6%, and 69.6% on liquid culture. More participants experienced a grade 3-5 AE at higher doses (37.0% and 16.0% in the highest and lowest dose groups, respectively;
  
   = 0.042, Cochran-Armitage test for trend) and higher tertiles of AUC (
  
   = 0.011).
  
  As part of a multidrug regimen, doses of levofloxacin >1,000 mg/d resulted in greater exposures and increased frequency of AEs but did not result in faster time to sputum culture conversion. A dose of 1,000 mg/d can achieve the target exposure in nearly all adults and was well tolerated. Clinical trial registered with www.clinicaltrials.gov (NCT01918397).
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Levofloxacin
  • Male
  • Female
  • Tuberculosis, Multidrug-Resistant
  • Adult
  • Middle Aged
  • Antitubercular Agents
  • Treatment Outcome
  • Dose-Response Relationship, Drug
  More +
• Keywords:
  • levofloxacin
  • MDR-TB
  • TB
  • double-blind randomized controlled trial
• Source:
  American Journal of Respiratory and Critical Care Medicine, 2025, v. 211, no. 7
• DOI:
  https://doi.org/10.1164/rccm.202407-1354OC
• ISSN:
  1073-449X ; 1535-4970
• Pubmed ID:
  40080768
• Pubmed Central ID:
  PMC12213226
• Document Type:
  Text
• Funding:
  R01 AI119037/AI/NIAID NIH HHSUnited States/ ; U01AI100805/Division of Microbiology and Infectious DiseasesUnited States/ ; R01 GM122876/GM/NIGMS NIH HHSUnited States/ ; U01 AI100805/AI/NIAID NIH HHSUnited States/ ; R01 AI124217/AI/NIAID NIH HHSUnited States/ ; CC/CDC HHSUnited States/ ; P30 AI168386/AI/NIAID NIH HHSUnited States/ ; K24 AI114444/AI/NIAID NIH HHSUnited States/ ; CC999999/ImCDC/Intramural CDC HHSUnited States/ ; P30 AI042853/AI/NIAID NIH HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  South Africa
• Pages in Document:
  1277-1287 (24 pdf pages)
• Volume:
  211
• Issue:
  7
• Download URL:
  https://stacks.cdc.gov/view/cdc/261601/cdc_261601_DS1.pdf
• File Type:
  [PDF - 1.24 MB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:6b8fc7a17dd464518dce0a78f4932baeb263a672a3e7933f152c4470897c941daa3c2079fab5766ff5e5580c8b26f6fc5f4816ce540a2d1b9055a717d0b5295b